Merit Medical acquires remaining stake in Solo Pace for about $45 million

• Merit Medical acquired Solo Pace's remaining outstanding equity for approximately $45 million on October 13, 2026.
• It previously owned approximately 18% through agreements totaling $5 million, covering shares, an acquisition option and exclusive distribution rights.
• The acquisition expands its Cardiac Therapies platform with temporary pacing technology for transcatheter aortic valve replacement and other transcatheter heart valve procedures.
• The transaction is expected to have an immaterial impact on previously forecast full-year 2026 revenue and earnings.
• For 2027, the acquisition is projected to be slightly accretive to non-GAAP earnings but slightly dilutive to GAAP earnings, becoming accretive thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291603PRIMZONEFULLFEED9854630) on October 29, 2026, and is solely responsible for the information contained therein.